A new test seems to be able to stratify patients at risk for progressive multifocal leukoencephalopathy (PML) while receiving the multiple sclerosis (MS) drug natalizumab more effectively than anything available at present.
The test is based on observations that patients who develop PML appear to have very low levels of L-selectin (CD62L) on CD4+ T cells in the months or years before they develop the condition..... Read More - http://www.ms-uk.org/tysabri
PML risk with Natalizumab in MS identified with new test
PML risk with Natalizumab in MS identified with new test
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 949 Views
-
Last post by frodo
-
- 0 Replies
- 1378 Views
-
Last post by frodo
-
- 0 Replies
- 2173 Views
-
Last post by NHE
-
- 6 Replies
- 4695 Views
-
Last post by ElliotB
-
- 0 Replies
- 1277 Views
-
Last post by NHE
-
- 0 Replies
- 3243 Views
-
Last post by NHE
-
- 0 Replies
- 1558 Views
-
Last post by NHE
-
- 0 Replies
- 956 Views
-
Last post by frodo
-
- 0 Replies
- 1458 Views
-
Last post by frodo